{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:50:12Z","timestamp":1785880212983,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205801"],"award-info":[{"award-number":["205801"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cllc.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:22:31Z","timestamp":1775690551000},"page":"65-76.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ENTR\u00c9E Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced\/Recurrent NSCLC"],"prefix":"10.1016","volume":"27","author":[{"given":"Marina Chiara","family":"Garassino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Gladkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina H.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antara","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua Jeremy","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie O.","family":"Karpinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hirschfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.04.003_bib0001","unstructured":"Cancer.Net. Lung cancer: non-small cell: statistics. https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics. Accessed: April 20, 2022."},{"key":"10.1016\/j.cllc.2026.04.003_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2026.04.003_bib0003","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.003_bib0004","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0006","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.003_bib0007","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.003_bib0008","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines(R) insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2026.04.003_bib0009","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) \u2013 novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cllc.2026.04.003_bib0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.003_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.003_bib0013","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2026.04.003_bib0014","unstructured":"Taxotere PI. https:\/\/products.sanofi.us\/taxotere\/taxotere.pdf. Accessed: October 13, 2025."},{"key":"10.1016\/j.cllc.2026.04.003_bib0015","unstructured":"Taxotere SmPC. https:\/\/www.medicines.org.uk\/emc\/product\/7206\/smpc\/print. Accessed: October 13, 2025."},{"key":"10.1016\/j.cllc.2026.04.003_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.678409","article-title":"Hyperprogressive disease in cancers treated with immune checkpoint inhibitors","volume":"12","author":"Shen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2026.04.003_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14728222.2018.1444753","article-title":"Inducible co-stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy","volume":"22","author":"Amatore","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.cllc.2026.04.003_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coi.2010.01.001","article-title":"Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)","volume":"22","author":"Simpson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0021","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","article-title":"Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg\/kg within an expanded access programme","volume":"62","author":"Di Giacomo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2026.04.003_bib0022","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cllc.2026.04.003_bib0024","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2767-9764.CRC-22-0293","article-title":"Activating inducible T-cell costimulator yields antitumor activity alone and in combination with anti-PD-1 checkpoint blockade","volume":"3","author":"Yadavilli","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.cllc.2026.04.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT178","article-title":"Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and\/or homologous recombination deficiency (HRD): initial results of the phase 2 KEYLYNK-007 study","volume":"81","author":"Maio","year":"2021","journal-title":"Cancer Research"},{"key":"10.1016\/j.cllc.2026.04.003_bib0026","series-title":"Inducible T-cell Co-stimulatory (ICOS) receptor agonist, GSK3359609, alone and in combination with pembrolizumab: preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)","author":"Rischin","year":"2019"},{"key":"10.1016\/j.cllc.2026.04.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011475","article-title":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors","volume":"13","author":"Maio","year":"2025","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.cllc.2026.04.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003026","article-title":"Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma","volume":"10","author":"Haddad","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2026.04.003_bib0029","doi-asserted-by":"crossref","first-page":"eabi8618","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.cllc.2026.04.003_bib0030","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0031","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/PO.21.00182","article-title":"Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"5","author":"Weber","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0032","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.04.003_bib0033","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.003_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0036","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1200\/JCO.2012.42.6932","article-title":"Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial","volume":"30","author":"Ramlau","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0037","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","article-title":"Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial","volume":"6","author":"Arrieta","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.04.003_bib0038","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.cllc.2026.04.003_bib0039","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:26Z","timestamp":1785878786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525730426000549"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENTR\u00c9E Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced\/Recurrent NSCLC","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}